Immortalizing Enzyme Does Not Make Human Cells Cancerous

December 28, 1998

DALLAS - December 29, 1998 - Scientists at UT Southwestern Medical Center at Dallas have shown that human cells grown in the laboratory and immortalized by the introduction of the enzyme telomerase are not transformed into cancer cells, perhaps clearing the way for safe, future medical applications.

Drs. Jerry Shay and Woodring Wright, UT Southwestern professors of cell biology and neuroscience, and their colleagues will report in the January 1999 issue of Nature Genetics that cells immortalized with telomerase, now more than 220 generations past their normal life span of 75 to 80 divisions, remain young and vigorous.

The cells exhibited none of the characteristics associated with cancer cells, such as chromosome instability, serum-independent growth, loss of contact inhibition and loss of cell-cycle checkpoint controls. In an accompanying article, collaborators at the Geron Corporation and academic colleagues demonstrate that the cells with introduced telomerase do not produce tumors in mice.

The fear that telomerase may cause cancer resulted because telomerase activity is a marker of cancer cells. While most normal cells, which have finite life spans, do not contain telomerase, more than 90 percent of cancer cells, which divide indefinitely, do.

"We clearly demonstrate that the expression of telomerase in cultured human cells does not cause cancer progression," said Wright, thereby reducing concerns that telomerase might act as an oncogene, a gene that can induce a cell to become malignant. "The abnormalities seen in cancer cells are due to other mutations; telomerase merely allows the cells to keep dividing."

A year ago the same researchers reported in Science (279:349-52, 1998) that telomerase introduced into human cells grown in the laboratory was sufficient to immortalize them. Their report proved that progressive shortening of telomeres - specific short pieces of deoxyribonucleic acid (DNA) that the enzyme telomerase adds back to the tips of chromosomes - is the biological clock that governs how many divisions a cell will go through.

With the new findings, the way now seems clear for research into new therapies for age-related diseases and for cancer - two ends of the same spectrum. The scientists emphasize, however, that additional studies will be necessary before the concepts are applied to humans.

"In the future I predict we will be attacking cancer by new combinatorial therapeutic approaches using DNA synthesis inhibitors, angiogenic inhibitors and telomerase inhibitors," Shay said. "The combination of these inhibitors would not only prevent the tumor from getting bigger, but each time the tumor cells divided, their telomeres would shorten. Eventually the cells would be unable to divide, and die."

The ability to immortalize human cells and retain normal behavior holds promise in several areas including biopharmaceutical research and transplantation medicine. The scientists believe this new technology has the potential to produce unlimited quantities of normal human cells of virtually any tissue type. Permanent, stable sources for normal human cells # instead of the animal cells or abnormal transformed human cells now available # may help in drug development, screening and testing. Genetic engineering of telomerase-immortalized cells also could help develop cellular models of human disease.

In the future it should be feasible to immortalize a patient's own blood stem cells, eliminating the need for donor bone marrow and avoiding immune rejection. The same technology could be applied to the production of insulin-producing cells for patients with insulin-dependent diabetes mellitus; cartilage cells for those with osteoarthritis and rheumatoid arthritis; blood vessel-forming cells for cardiac patients with angina, stroke or arterial insufficiency; skin cells for burn patients and patients with severe wounds; muscle stem cells for treating muscular dystrophy patients; and the cosmetic production of collagen.

"The goal of our research is to increase our health span, not necessarily our life span, by finding out how to keep our aging - but healthy - cells growing and how to make our cancer cells senescent," said first author Dr. Carmela Morales, a research fellow in internal medicine and a Robert Wood Johnson scholar. "We believe that telomerase is an important target both for the potential treatment of age-related disease and for cancer."

Other UT Southwestern investigators involved in this research included former research fellow Dr. Shawn Holt; cell biology and neuroscience research fellows Dr. Michel Ouellette and Dr. Kiran Kaur; pharmacology research fellow Dr. Ying Yan; Dr. Michael White, assistant professor of cell biology and neuroscience; and Dr. Kathleen Wilson, assistant professor of pathology.

The investigators' Web site is at:
This news release is available on our World Wide Web home page at To automatically receive news releases from UT Southwestern via e-mail, send a message to Leave the subject line blank and in the text box, type SUB UTSWNEWS

UT Southwestern Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to